The Next AI Biotech Boom Is Here: 7 Stocks Under $50B You Need to See | MIT LIVE

Seven AI Biotech Stocks Under $50 Billion

Overview of Market Conditions

• Jonathan introduces the topic of seven AI biotech stocks under a $50 billion market cap, emphasizing the search for smaller companies that have not yet gained significant attention.

• He discusses current market dislocation due to rising bond yields and contrasting performance in the NASDAQ, indicating an unsustainable situation that could lead to corrections.

Market Analysis

• The TLT (iShares 20+ Year Treasury Bond ETF) is highlighted as continuing to decline, suggesting that increasing bond volatility may lead to a downturn in the stock market.

• Jonathan warns against investing heavily in NASDAQ stocks at their highs, predicting potential corrections if bond prices do not stabilize.

Introduction to AI Biotech Stocks

• The focus shifts to biotech stocks, which are less correlated with overall tech trends. Jonathan lists seven specific AI biotech stocks worth watching.

Key Stock Insights

KOD (Kodiak Sciences)

• KOD is noted for its recent revaluation based on positive data outcomes and increased trading volume, making it a strong candidate for investment.

BMRN (BioMarin Pharmaceutical)

• BMRN's expected move pricing indicates stability; it has historically closed within its expected range 87.5% of the time over two years.

PGEN (Precigen)

• PGEN has received FDA platform technology designation, allowing it multiple regulatory pathways and clinical catalysts from one validated platform.

ABPSY (Apsy)

• Apsy is recognized as a direct AI-to-clinic name with significant growth potential due to its global phase 2 study involving generative AI-engineered drugs.

RXRX (Recursion Pharmaceuticals)

• RXRX shows institutional interest through IPO filings and unusual options activity, indicating strong market appetite for AI-driven drug development.

Trading Strategies and Recommendations

• Jonathan emphasizes monitoring unusual option activity as a key strategy for identifying promising trades in these biotech stocks.

• He suggests using vertical spreads as an effective way to manage risk while investing in these high-potential biotech names.

Conclusion and Future Outlook

• The session wraps up with reminders about upcoming economic events that may influence market volatility and encourages viewers to engage with future content.